Integration Update: Expanded FAQ for Advarra Merger Efforts
The Advarra team (formerly Chesapeake IRB and Schulman IRB) continues to integrate our processes and policies, leveraging mutual strengths in
The Advarra team (formerly Chesapeake IRB and Schulman IRB) continues to integrate our processes and policies, leveraging mutual strengths in
Clinical research continues to grow throughout the world, with researchers looking outside the US for new and diverse subject populations to help develop and improve investigational therapies.
New to clinical research? Learn the meaning of common industry acronyms and abbreviations including eCRF, IIT, PI, TMF, and more.
Since November 2017, the Advarra team (formerly Chesapeake IRB and Schulman IRB) has been working to integrate our processes and
On November 7, 2017, we announced that Chesapeake IRB and Schulman IRB are merging under the new organizational name, Advarra.
Food and Drug Administration (FDA) regulations and the Common Rule require that the selection of participants in research is equitable.
Recently, the clinical research community has been making efforts to include more diverse subject populations in clinical studies. Sec. 907
At Advarra we’ve been seeing more and more eConsent studies recently, which is great—eConsent technology can often better inform participants
The completion of the human genome project and advances in genetic engineering have paved the way for clinical trials involving
A major element of any IRB review is the examination of potential benefits and risks to study participants. In studies
The popularity of adaptive design in clinical research continues to grow. Adaptive design can be more efficient than traditional study
Creating feasibility assessments can be as frustrating for sponsors as answering questionnaires is for sites. Here’s how sponsors can alleviate these frustrations, according to sites.